Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: Radiotherapy, Sintilimab, and Surufatinib in High-Risk Localized Soft Tissue Sarcoma
NCT05839275Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and sintilimab in soft tissue sarcoma (STS), sponsored by Fudan University. Primary endpoints: Objective Response Rate and Dose-Limiting Toxicity. Started Aug 2022; status: recruiting.
02
Drugs
surufatinibsintilimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05839275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839275.